Literature DB >> 22634361

Anxiolytic- but not antidepressant-like activity of Lu AF21934, a novel, selective positive allosteric modulator of the mGlu₄ receptor.

Anna Sławińska1, Joanna M Wierońska, Katarzyna Stachowicz, Agnieszka Pałucha-Poniewiera, Michelle A Uberti, Maria A Bacolod, Dario Doller, Andrzej Pilc.   

Abstract

Previous studies demonstrated that the Group III mGlu receptor-selective orthosteric agonist, LSP1-2111 produced anxiolytic- but not antidepressant-like effects upon peripheral administration. Herein, we report the pharmacological actions of Lu AF21934, a novel, selective, and brain-penetrant positive allosteric modulator (PAM) of the mGlu(4) receptor in the stress-induced hyperthermia (SIH), four-plate, marble-burying and Vogel's conflict tests. In all models, except Vogel's conflict test, a dose-dependent anxiolytic-like effect was seen. The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin. These results suggest that the GABAergic system, but not the serotonergic system, is involved in the mechanism of the anxiolytic-like phenotype of Lu AF21934 in rodents. Lu AF21934 did not produce antidepressant-like effects in the tail suspension test (TST) in mice; however, it decreased the basal locomotor activity of mice that were not habituated to activity cages. This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22634361     DOI: 10.1016/j.neuropharm.2012.05.001

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  19 in total

Review 1.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

2.  Dynamic modulation of inflammatory pain-related affective and sensory symptoms by optical control of amygdala metabotropic glutamate receptor 4.

Authors:  C Zussy; X Gómez-Santacana; X Rovira; D De Bundel; S Ferrazzo; D Bosch; D Asede; F Malhaire; F Acher; J Giraldo; E Valjent; I Ehrlich; F Ferraguti; J-P Pin; A Llebaria; C Goudet
Journal:  Mol Psychiatry       Date:  2016-12-20       Impact factor: 15.992

3.  Autistic-like syndrome in mu opioid receptor null mice is relieved by facilitated mGluR4 activity.

Authors:  Jérôme A J Becker; Daniel Clesse; Coralie Spiegelhalter; Yannick Schwab; Julie Le Merrer; Brigitte L Kieffer
Journal:  Neuropsychopharmacology       Date:  2014-03-12       Impact factor: 7.853

Review 4.  Development of allosteric modulators of GPCRs for treatment of CNS disorders.

Authors:  Hilary Highfield Nickols; P Jeffrey Conn
Journal:  Neurobiol Dis       Date:  2013-09-27       Impact factor: 5.996

5.  Viral vector mediated expression of mutant huntingtin in the dorsal raphe produces disease-related neuropathology but not depressive-like behaviors in wildtype mice.

Authors:  Mark Pitzer; Jordan Lueras; Anna Warden; Sydney Weber; Jodi McBride
Journal:  Brain Res       Date:  2015-02-28       Impact factor: 3.252

Review 6.  Therapeutic potential of targeting glutamate receptors in Parkinson's disease.

Authors:  Clare Finlay; Susan Duty
Journal:  J Neural Transm (Vienna)       Date:  2014-02-21       Impact factor: 3.575

7.  The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents.

Authors:  Anna Sławińska; Joanna M Wierońska; Katarzyna Stachowicz; Marcin Marciniak; Magdalena Lasoń-Tyburkiewicz; Piotr Gruca; Mariusz Papp; Magdalena Kusek; Krzysztof Tokarski; Darío Doller; Andrzej Pilc
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

8.  Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders.

Authors:  Mikhail Kalinichev; Emmanuel Le Poul; Christelle Boléa; Françoise Girard; Brice Campo; Massimiliano Fonsi; Isabelle Royer-Urios; Susan E Browne; Jason M Uslaner; Matthew J Davis; Jacob Raber; Robert Duvoisin; Simon T Bate; Ian J Reynolds; Sonia Poli; Sylvain Celanire
Journal:  J Pharmacol Exp Ther       Date:  2014-06-19       Impact factor: 4.030

9.  Facilitating mGluR4 activity reverses the long-term deleterious consequences of chronic morphine exposure in male mice.

Authors:  Jerome A J Becker; Lucie P Pellissier; Yannick Corde; Thibaut Laboute; Audrey Léauté; Jorge Gandía; Julie Le Merrer
Journal:  Neuropsychopharmacology       Date:  2020-12-21       Impact factor: 8.294

10.  Identification of positive allosteric modulators VU0155094 (ML397) and VU0422288 (ML396) reveals new insights into the biology of metabotropic glutamate receptor 7.

Authors:  Nidhi Jalan-Sakrikar; Julie R Field; Rebecca Klar; Margrith E Mattmann; Karen J Gregory; Rocio Zamorano; Darren W Engers; Sean R Bollinger; C David Weaver; Emily L Days; L Michelle Lewis; Thomas J Utley; Miguel Hurtado; Delphine Rigault; Francine Acher; Adam G Walker; Bruce J Melancon; Michael R Wood; Craig W Lindsley; P Jeffrey Conn; Zixiu Xiang; Corey R Hopkins; Colleen M Niswender
Journal:  ACS Chem Neurosci       Date:  2014-10-09       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.